Historical Stock Price
ABIO historical stock prices picture
ARCA biopharma (ABIO) has the following price history information. Looking back at ABIO historical stock prices for the last five trading days, on August 08, 2022, ABIO opened at $2.40, traded as high as $2.40 and as low as $2.33, and closed at $2.38. Trading volume was a total of 45.80K shares. On August 09, 2022, ABIO opened at $2.38, traded as high as $2.46 and as low as $2.37, and closed at $2.43. Trading volume was a total of 45.10K shares. On August 10, 2022, ABIO opened at $2.43, traded as high as $2.44 and as low as $2.35, and closed at $2.42. Trading volume was a total of 24.90K shares. On August 11, 2022, ABIO opened at $2.44, traded as high as $2.47 and as low as $2.38, and closed at $2.40. Trading volume was a total of 20.40K shares. On August 12, 2022, ABIO opened at $2.40, traded as high as $2.47 and as low as $2.39, and closed at $2.47. Trading volume was a total of 30.20K shares.

ABIO Historical Stock Prices By Date:

ABIO historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into ARCA biopharma shares, starting with a $10,000 purchase of ABIO, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/14/2012
End date: 08/12/2022
Start price/share: $257.04
End price/share: $2.47
Dividends collected/share: $0.00
Total return: -99.04%
Average Annual Total Return: -37.16%
Starting investment: $10,000.00
Ending investment: $96.02
Years: 10.00
Date Open High Low Close Volume
08/08/2022 $2.40 $2.40 $2.33 $2.38 45.80K
08/09/2022 $2.38 $2.46 $2.37 $2.43 45.10K
08/10/2022 $2.43 $2.44 $2.35 $2.42 24.90K
08/11/2022 $2.44 $2.47 $2.38 $2.40 20.40K
08/12/2022 $2.40 $2.47 $2.39 $2.47 30.20K
ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Date Close
08/08/2022$2.38
08/09/2022$2.43
08/10/2022$2.42
08/11/2022$2.40
08/12/2022$2.47
ABIO is categorized under the Healthcare sector; below are some other companies in the same sector:

ABMD Historical Stock Prices
ABT Historical Stock Prices
ABV Historical Stock Prices
ACAD Historical Stock Prices
ACER Historical Stock Prices
ACET Historical Stock Prices
ACHC Historical Stock Prices
ACHN Historical Stock Prices
ACHV Historical Stock Prices
ACOR Historical Stock Prices

Also explore: ABIO shares outstanding history

Email EnvelopeFree ABIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


ABIO Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.